Geron (NASDAQ:GERN) Posts Earnings Results, Hits Expectations

Geron (NASDAQ:GERN) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03), Zacks reports. Geron had a negative net margin of 43.61% and a negative return on equity of 29.63%.

Here are the key takeaways from Geron’s conference call:

• 2026 financial guidance reiterated — management expects RYTELO net revenue of $220–$240 million and total operating expenses of $230–$240 million, targeting quarter‑over‑quarter demand growth with a larger portion of revenue in the back half of 2026.
• Commercial execution focused on second‑line, lower‑risk MDS (~8,000 US patients) — Q4 showed 9% demand growth and a ~13% increase in prescribing accounts (to ~1,300), with a targeted field plus digital “3D surround sound” strategy prioritizing high‑volume community centers.
• Clinical and evidence‑generation catalysts ahead — the fully enrolled IMpactMF trial has an interim overall‑survival analysis expected in H2 2026 (final analysis planned H2 2028) and management expects initial investigator‑sponsored trial and real‑world evidence data in H2 2026.
• Cash runway and financing reliance — cash and marketable securities fell to approximately $400 million at year‑end (from $503 million), and access to an additional $125 million under an amended loan is only available through July 30, 2026, indicating potential near‑term financing needs.
• Rising gross‑to‑net deductions could pressure net revenue — gross‑to‑net increased to 17.7% in 2025 (from 14.5% in 2024) due to greater 340B use and GPO contracting, and management expects gross‑to‑net in the high‑teens to low‑twenties in 2026.

Geron Stock Performance

Shares of GERN stock traded down $0.34 during trading on Wednesday, reaching $1.62. 18,749,286 shares of the company’s stock were exchanged, compared to its average volume of 14,507,861. Geron has a twelve month low of $1.04 and a twelve month high of $2.01. The firm’s fifty day moving average price is $1.46 and its 200-day moving average price is $1.35. The company has a quick ratio of 4.87, a current ratio of 5.96 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $1.03 billion, a PE ratio of -13.54 and a beta of 0.62.

More Geron News

Here are the key news stories impacting Geron this week:

• Positive Sentiment: RyTELO commercial momentum — Geron reported RYTELO net product revenue of $48.0M in Q4 and $183.6M for full‑year 2025, with RYTELO demand up 9% sequentially and ~150 new ordering accounts added in Q4, supporting continued top‑line growth. Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
• Positive Sentiment: 2026 revenue guidance reiterated — Management reiterated 2026 RYTELO net product revenue guidance of $220M–$240M, indicating confidence in commercial outlook and providing a measurable growth target for investors. Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
• Neutral Sentiment: Cash runway and cost discipline — Geron ended 2025 with about $401M in cash and marketable securities and reported 2025 operating expense of ~$255M (within prior guidance); management says current resources plus anticipated U.S. RYTELO sales should fund foreseeable needs, but the cash decline from 2024 is notable. Geron Corporation Reports $184 Million in RYTELO® Revenue for 2025 and Provides 2026 Financial Guidance
• Neutral Sentiment: Upcoming catalysts — Management flagged mid‑2026 milestones (IMpactMF interim analysis, initial real‑world trials in LR‑MDS) and scheduled investor presentations (TD Cowen, Barclays) that could move sentiment if results/data surprise. Geron Plans to Present at Upcoming Investor Conferences
• Negative Sentiment: Quarterly loss and perceived miss — The company reported a Q4 net loss of $31.1M and EPS roughly in line with consensus (‑$0.03), but some investors/analysts viewed the results and accompanying metrics as a miss versus expectations, contributing to selling pressure. Geron falls as Q4 results miss expectations
• Negative Sentiment: Restructuring and expense execution — Geron recorded $17M of restructuring charges after cutting ~1/3 of its workforce; SG&A rose as the company invested in sales/marketing. Combined with the cash decline from ~$503M to ~$401M, investors are focused on near‑term cash burn and execution risks. Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
• Negative Sentiment: Analyst reactions and valuation pressure — Some analyst coverage has been cautious (e.g., TD Cowen trimmed its price target earlier), and recent commentary about valuation vs. volatility has kept trading active and pressure on the shares. Geron (GERN) Sets 2026 Financial Goals, TD Cowen Cuts PT

Hedge Funds Weigh In On Geron

Several institutional investors and hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Geron by 2.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 392,534 shares of the biopharmaceutical company’s stock worth $627,000 after buying an additional 8,123 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Geron by 8.3% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,372,016 shares of the biopharmaceutical company’s stock worth $2,182,000 after acquiring an additional 104,840 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of Geron by 8.3% during the second quarter. Legal & General Group Plc now owns 550,871 shares of the biopharmaceutical company’s stock worth $775,000 after acquiring an additional 42,345 shares during the period. Rhumbline Advisers grew its position in shares of Geron by 4.1% in the second quarter. Rhumbline Advisers now owns 873,893 shares of the biopharmaceutical company’s stock valued at $1,232,000 after purchasing an additional 34,437 shares during the last quarter. Finally, Prudential Financial Inc. grew its position in shares of Geron by 72.3% in the second quarter. Prudential Financial Inc. now owns 79,494 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 33,352 shares during the last quarter. 73.71% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on GERN shares. Weiss Ratings restated a “sell (e+)” rating on shares of Geron in a research note on Wednesday, January 28th. UBS Group restated a “neutral” rating on shares of Geron in a research note on Tuesday, December 9th. Needham & Company LLC lowered their price target on Geron from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. TD Cowen reiterated a “buy” rating on shares of Geron in a research note on Thursday, January 29th. Finally, HC Wainwright reissued a “neutral” rating on shares of Geron in a research note on Tuesday, December 9th. Four investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $2.75.

About Geron

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.